Completed PHASE2 INTERVENTIONAL 1-arm NCT01462695

Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma

A Phase II Study of Sunitinib (NSC# 736511) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients

Sponsor: National Cancer Institute (NCI)

Conditions Childhood Cerebellar Anaplastic Astrocytoma Childhood Cerebral Anaplastic Astrocytoma Childhood Cerebral Astrocytoma Childhood Infratentorial Ependymoma Childhood Mixed Glioma Childhood Oligodendroglioma Childhood Supratentorial Ependymoma Recurrent Childhood Cerebellar Astrocytoma Recurrent Childhood Cerebral Astrocytoma Recurrent Childhood Ependymoma Recurrent Childhood Subependymal Giant Cell Astrocytoma

Interventions Diagnostic Laboratory Biomarker Analysis Pharmacological Study Sunitinib Malate

Updated 7 times since 2017 Last updated: Aug 18, 2015 Started: Jan 31, 2012 Primary completion: Dec 31, 2013 Completion: Mar 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Childhood Cerebellar Anaplastic Astrocytoma and Childhood Cerebral Anaplastic Astrocytoma and is currently completed. National Cancer Institute (NCI) leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Albuquerque, United States , Atlanta, United States , Austin, United States , Birmingham, United States , Boston, United States , Buffalo, United States , Chapel Hill, United States , Charlotte, United States , Chicago, United States and 72 more locations